Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis.
Ontology highlight
ABSTRACT: Objective:To provide real-world data and summarize current clinical evidence on the efficacy and safety of sirolimus in active systemic lupus erythematosus (SLE) patients. Methods:This was a prospective real-world clinical study. Included SLE patients should have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)???2. They were treated with sirolimus and followed up regularly. The SLEDAI-2K, Physician Global Assessment (PGA), serological activity indices, and remission of organ manifestations were evaluated. We also performed a meta-analysis to integrate current evidence of sirolimus in SLE. Results:A total of 49 patients were included in the final analysis. After treatment, the SLEDAI-2K (6.2?±?3.1 versus 4.0?±?3.4, p?=?0.001) decreased significantly, and the prednisone dosage was tapered successfully (9.9?±?8.8?mg/day versus 5.9?±?4.0?mg/day, p?=?0.002). Serological activity indices also improved [complement 3 (C3): 0.690?±?0.209?g/l versus 0.884?±?0.219?g/l, p?
SUBMITTER: Peng L
PROVIDER: S-EPMC7493251 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA